U.S. Markets closed

Tonix Pharmaceuticals Holding Corp. (TNXP)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
0.6300+0.0176 (+2.87%)
At close: 4:00PM EST
Sign in to post a message.
  • D
    The development of artificial antigen-presenting cells, where immortalized cells are transduced with lentiviruses to effectively mimic antigen-presenting cells, as is the case for COVID-19/aAPC. Extra cold-chain requirements for a cell-based vaccine and infusion procedures hamper the deployment of these vaccines on a large scale, even more so since multiple doses are required for an efficient response. COVID-19 vaccines based on all next-generation platforms are currently in clinical trials; some of these have already moved from phase 1 into phase 2.
  • P
    added 3x in $0.50s over past month
    and added again for last time today around 0.61 ....
    my avg is around 0.6us
    my position is now complete and ready for phase 3 fibro which i believe
    have good odds ( 65-70%) of meeting primary end point and i think stock will goto
    1.3-1.5 range on good data and 1.5-2 range on strong data ( p value < 0.01) with possible pre mkt spike to 2-2.5 range ....

    and those ranges are from a starting based of around $0.8 ( where i think the stock will run up to before the phase 3 release) .... but if it doesnt and stays here at $0.6- then subtract $0.2 from the post phase 3 ranges i mentioned.....

    data will be here anytime between now and Dec. 31 - there are no guarantees about anything in life except death and taxes...but im feeling good about these phase 3 results ....based on the phase 3 data for fibro in 2016 that failed but actually would have met the primary end point using the current FDA protocol.....
  • E
    I have updated my estimates with the preclinical data on TNX-1800 and the fact that they are seeking a new statistical method that will give us a much higher chance of success. If the FDA approves this new way of looking at psychopharmacological data it would be a major game changer.

    Indication Market US$ approval%p peak share earliest time Net cur.val.
    TNX-102 CycloB
    Fibro 3 500 000 000 90 % 20 % 2021 630 000 000
    PTSD 8 200 000 000 45 % 15 % 2022 553 500 000
    Alz.ag. 12 430 000 000 5 % 5 % 2024 31 075 000
    AlcoholUD36 000 000 000 10 % 5 % 2024 180 000 000
    Covid-19 100 000 000 000 8 % 5 % 2021 400 000 000
    Covid-19 100 000 000 000 2 % 4 % 2022 80 000 000
    Cocain intox 2 000 000 000 25 % 100 % 2022 500 000 000
    Dep+PTSD 28 600 000 000 3 % 2 % 2022 17 160 000
    Dep+PTSD 28 600 000 000 3 % 2 % 2025 17 160 000
    Migrene 3 510 000 000 5 % 1 % 2025 1 755 000
    G/P cancer 11 200 000 000 1 % 3 % 2026 3 360 000
    Immune 1 200 000 000 2 % 5 % 2026 1 200 000
    Total value: 2 415 210 000

    The new estimate gives a valuation of about 2.4B, or more than $15 per share. With a 70% discount the share price should be around $5. In a buyout situation they could ask for about 50% discount, which would give about $8 per share.
  • S
    You guys think this will reach $2
  • S
    Just bought 10000 shares Let’s hope for that $3 pay out long term
  • R
    I'm guessing results are positive for the Fibro, someone bought 3,000,000 shares yesterday around 1:45. Anyone willing to spend that kind of money already knows this thing is going to the moon
  • U
    I have this gut feeling the results are negative. Why wait to release if positive?!
  • M
    The shadow is BlackRock. They purchased almost 1.5 million shares less than 60 days ago. For the People woh don’t know, BlackRock, Inc. is an American global investment management corporation based in New York City. Founded in 1988, initially as a risk management and fixed income institutional asset manager, BlackRock is the world's largest asset manager, with $7.4 trillion in assets under management as of end-Q4 2019. BlackRock operates globally with 70 offices in 30 countries and clients in 100 countries.Due to its power, and the sheer size and scope of its financial assets and activities, BlackRock has been called the world's largest shadow bank. Along with Vanguard and State Street, BlackRock is considered one of the Big Three index funds that dominate corporate America.
  • T
    Tonix Pharmaceuticals Holding Corp. (TNXP) announced last month that the first patient was enrolled in the observational COV-LOGIC study (TNX-C001), a study of humoral (antibody) and cellular (T cell) immune responses to SARS-CoV-2 in volunteers who have recovered or remain asymptomatic after exposure to COVID-19. The research is part of an ongoing and broader collaboration between Tonix and Southern Research to develop and conduct animal testing of Tonix's TNX-1800, which is a live replicating, attenuated virus vaccine designed to protect against COVID-19. "This represents a significant milestone for the Company as the data we plan to collect from recovered and asymptomatic COVID-19 volunteers in this study will help inform vaccine development on how to safely provide the same immune responses that others got from recovering from actual SARS-CoV-2 infection," said Seth Lederman, M.D., President and CEO of Tonix. "Our goal with TNX-1800 is to develop a vaccine that is well tolerated, produces strong, long-lasting immunity, and can be rapidly and broadly deployed. The features of a protective immune response to SARS-CoV-2 remain unknown. But since SARS-CoV-2 is a virus, we believe that T cell responses, in particular T Helper Type 1, or TH1 responses, will play an important, if not dominant, role in protecting against serious illness from COVID-19."
  • M
    “Wall Street analysts have a consensus price target for the stock at $3, which means that the shares’ value could jump 383.87% from current levels.”
    Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Forecast to gain 383.87% to hit Consensus price target – Marketing Sentinel
  • T
    Technical Support
    Looking at the charts, a huge breakout is forming, just be patient!
  • M
    Latest Institutional Activity
    BLACKROCK FUND ADVISORS  Bought 1.5 Million shares of Tonix Pharmaceuticals 9/30/2020
    GEODE CAPITAL MANAGEMENT LLC  Bought 611.1 Thousand shares of Tonix Pharmaceuticals 9/30/2020
    SQUAREPOINT OPS LLC  Bought 311.9 Thousand shares of Tonix Pharmaceuticals.
    BlackRock Fund Advisors
    Geode Capital Management LLC
    The Vanguard Group, Inc.
    Squarepoint OPS LLC
    Bridgeway Capital Management, Inc...
    Northern Trust Investments, Inc.(...
    Charles Schwab Investment Managem...
    Millennium Management LLC
    GSA Capital Partners LLP
    Citadel Advisors LLC
  • J
    $GTE conversation
    Hey Howard, feeling de-masculated today? $0.30 cent today......$2 Fall 2021 for $GTE. Oil Rocks!!!!!
  • A
    It will pass $2 end of year.
    Buy all you can today!
    Just watch it.

    Good luck all!
  • C
    Good news: Press Releases

    Vaccine Genome Researchers Report 99.7% Colinear Identity Between a U.S. Civil War Era Smallpox Vaccine and Horsepox Virus
  • T
    What if fibro is positive ? Straight to 0,99 ? Or 1,5 ? And then sell ?
  • m
    Nobody making covid19 vaccine for animals. tnxp is the only one.... Target Price $2.50!
  • L
    A 4 date rally could only yield 4 cents
  • L
    “The new findings are particularly significant, because they confirm that horsepox has been used as a safe and effective smallpox vaccine since at least 1860, and probably since Edward Jenner’s time in 1798,” continued Dr. Lederman. … Dr. Lederman continued, “Smallpox was eradicated using single-dose live replicating vaccines that induce durable T cell immunity, prevent serious illness after infection and block forward transmission. Our hope and our goal is to produce vaccines that will provide long term immunity with a single dose using a proven technology that can be readily scaled up for manufacturing and that does not require a costly and cumbersome cold chain for distribution and storage.”
  • J
    If you read back it will tell you why the prices are here and that it will double after the buying is done... Good Luck